News Sentiment

PRLD sentiment intelligence

Prelude Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.81 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-2.1% over one week, +7.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -2.1% Price reacting lower
Trend fit Trend active 7.0% over four weeks
Fair value 79.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 8
marketscreener.com 6
TradingKey 5
dars.gov.et 4
Investing.com 4
TradingView 4
Moomoo 3

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 22
Analyst action 7
Regulatory and legal 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
marketscreener.com Direct company coverage

Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2500 Growth Benchmark

Prelude Therapeutics Incorporated (NasdaqGS:PRLD) has been added to the Russell 2500 Growth Benchmark. This news coincides with several other Russell index additions for Prelude Therapeutics on the same day, including the Russell Small Cap Comp Growth Benchmark, Russell 2000 Inde

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 20:09
Source
marketscreener.com
marketscreener.com Direct company coverage

Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 2500 Index

Prelude Therapeutics Incorporated (NasdaqGS:PRLD) has been added to the Russell 2500 Index. This inclusion is part of a broader set of additions to various Russell indices, including the Russell Small Cap Comp Growth Benchmark, Russell 2500 Growth Benchmark, Russell 2000 Index, R

Tone
Positive 73/100
Event
Market update
Published
29 Jun 2026 08:41
Source
marketscreener.com
marketscreener.com Direct company coverage

Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Microcap Growth Benchmark Index

Prelude Therapeutics Incorporated (NasdaqGS:PRLD) has been added to the Russell Microcap Growth Benchmark Index. The company is a precision oncology firm focused on developing novel cancer medicines, with a pipeline including kinases, targeted protein degraders, and degrader anti

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 08:16
Source
marketscreener.com
TradingKey Direct company coverage

Prelude Therapeutics Inc (PRLD) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Prelude Therapeutics Inc (PRLD), highlighting its current valuation score of 6.01, which ranks it 367 out of 389 in the Biotechnology & Medical Research industry. It notes the company's current P/E ratio of -4.34, which is significantly belo

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 12:09
Source
TradingKey
TradingKey Direct company coverage

Prelude Therapeutics Inc (PRLD) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Prelude Therapeutics Inc (PRLD), detailing its current stock price momentum, support and resistance levels, and indicator and moving average readings as of June 18, 2026. The stock is currently trading between $3.58 and $4.87, with va

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 23:39
Source
TradingKey
TradingKey Direct company coverage

Prelude Therapeutics Inc (PRLD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Prelude Therapeutics Inc (PRLD), including its major individual and institutional investors. Key shareholders like OrbiMed Advisors, Baker Bros. Advisors LP, and RA Capital Management LP are highlighted, along with a breakdown of

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:57
Source
TradingKey
TradingKey Direct company coverage

Prelude Therapeutics Inc (PRLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article for Prelude Therapeutics Inc (PRLD) states that relevant data regarding the company's revenue breakdown by business segment and by region have not yet been disclosed. It indicates that the company's financial information in these specific categories is currently unav

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:40
Source
TradingKey
Moomoo Direct company coverage

Market Sentiment Around Loss-Making Prelude Therapeutics Incorporated (NASDAQ:PRLD)

This article examines the market sentiment surrounding Prelude Therapeutics (NASDAQ:PRLD), a loss-making biotechnology company. It highlights that despite recent positive movements in its stock price, analysts have maintained a bearish stance with an average price target indicati

Tone
Neutral 50/100
Event
Analyst action
Published
17 Jun 2026 13:11
Source
Moomoo
TradingKey Direct company coverage

Prelude Therapeutics Inc (PRLD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Prelude Therapeutics Inc (PRLD) has an earnings forecast score of 8.67, ranking it 71st in the Biotechnology & Medical Research industry. Analysts project an average price target of $4.00, with an upside potential of 79.37%. Most analysts currently rate PRLD as a "Buy."

Tone
Positive 65/100
Event
Earnings
Published
16 Jun 2026 23:09
Source
TradingKey
Stock Titan Direct company coverage

Prelude Therapeutics (PRLD) shareholders back directors, auditor and say-on-pay

Prelude Therapeutics shareholders approved all proposals at their 2026 Annual Meeting. They re-elected three Class III directors (Krishna Vaddi, Paul Scherer, and Katina Dorton), ratified Ernst & Young LLP as the independent auditor for 2026, and gave advisory approval for 2025 e

Tone
Neutral 50/100
Event
Regulatory and legal
Published
11 Jun 2026 10:40
Source
Stock Titan
Stock Titan Direct company coverage

Prelude Therapeutics (PRLD) director receives 38,000 stock options at $3.94 strike

Prelude Therapeutics director Paul A. Friedman was granted 38,000 stock options at an exercise price of $3.94 per share, expiring on June 8, 2036. These options are part of his board compensation and will vest on the earlier of the company’s next annual stockholder meeting or one

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 09:10
Source
Stock Titan
Stock Titan Direct company coverage

Director at Prelude Therapeutics (PRLD) awarded 38,000 stock options

Prelude Therapeutics Inc. director Katina Dorton was granted 38,000 stock options with an exercise price of $3.94 per share, expiring on June 8, 2036. The options will fully vest on the earlier of the next annual stockholder meeting or the one-year anniversary of the grant date,

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 22:09
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Prelude Therapeutics Inc Insider Trading Activity

Prelude Therapeutics Inc. director David P. Bonita was granted 38,000 stock options with an exercise price of $3.94 per share, expiring on June 8, 2036. The options will vest upon the company's next annual stockholder meeting or the one-year anniversary of the grant date, conting

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

PRLD: All director, auditor, and executive compensation proposals were approved by shareholder vote

Shareholders of Prelude Therapeutics Incorporated (PRLD) approved all proposals at their recent annual general meeting. This included the election of three directors, ratification of the company's auditor, and approval of executive compensation and its annual review. The final re

Tone
Positive 71/100
Event
Regulatory and legal
Published
09 Jun 2026 13:10
Source
TradingView
Finviz Direct company coverage

PRLD - Prelude Therapeutics Inc Stock Price and Quote

This page provides detailed stock information for Prelude Therapeutics Inc (PRLD), including its current stock price, financial metrics, analyst ratings history, and recent news. It lists key financial data, performance indicators, insider transactions, and a chronological news f

Tone
Neutral 50/100
Event
Analyst action
Published
29 May 2026 15:41
Source
Finviz
Simply Wall Street Direct company coverage

Prelude Therapeutics (Nasdaq:PRLD) - Stock Analysis

This extensive analysis of Prelude Therapeutics (PRLD) covers its stock performance, financial health, and pipeline developments. The company, a clinical-stage precision oncology firm, is currently unprofitable but forecasts strong revenue growth. Recent updates include positive

Tone
Negative 40/100
Event
Earnings
Published
20 May 2026 11:12
Source
Simply Wall Street
Sahm Direct company coverage

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Following its first-quarter results, Prelude Therapeutics (NASDAQ:PRLD) saw a dip in share price, but analysts quickly upgraded their estimates. Revenue forecasts for 2026 increased to US$27.3m, and the projected loss per share significantly narrowed to US$0.37. The company's pri

Tone
Positive 82/100
Event
Earnings
Published
17 May 2026 10:40
Source
Sahm